KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
Carcinoma, Neuroendocrine
DRUG: Selinexor
Overall Response Rate, To evaluate the efficacy of single agent Selinexor in patients with poorly differentiated lung and gastroenteropancreatic (GEP) neuroendocrine tumors (NET) as determined by overall response rate (ORR) including complete (CR) and partial (PR) response., Every 8 weeks from screening until documented disease progression or date of death, whichever occurs first, up to approximately 100 months.
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors in adult patients age \>/= to 18.